Effect of Clinical Typing on Serum Urate Targets of Benzbromarone in Chinese Gout Patients: A Prospective Cohort Study

Frontiers in Medicine

Medicine

Xiaomei Xue¹  Fei Yan¹  Jie Lu²  Changgui Li³  Wenyan Sun⁴  Xuan Yuan⁴  Tony R. Merriman⁵  Can Wang⁶  Lingling Cui⁶  Zhen Liu⁶  Aichang Ji⁶  Lin Han⁶  Xinde Li⁶  Yuwei He⁶ 

[1] Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China;Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China;Institute of Metabolic Diseases, Qingdao University, Qingdao, China;Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, The Affiliated Hospital of Qingdao University, Qingdao, China;Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China;Institute of Metabolic Diseases, Qingdao University, Qingdao, China;Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, The Affiliated Hospital of Qingdao University, Qingdao, China;Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Qingdao, China;Institute of Metabolic Diseases, Qingdao University, Qingdao, China;Institute of Metabolic Diseases, Qingdao University, Qingdao, China;Department of Biochemistry, University of Otago, Dunedin, New Zealand;Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Birmingham, AL, United States;Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, The Affiliated Hospital of Qingdao University, Qingdao, China;

关键词: gout;    clinical typing;    serum urate target;    low-dose benzbromarone;    urate-lowering therapy;   

DOI  :  10.3389/fmed.2021.806710

 received in 2021-11-01, accepted in 2021-12-20,  发布年份 2022

来源: Frontiers

【 摘 要 】

IntroductionAchieving a goal of serum urate levels in patients with gout is an important way to prevent gout and its complications while it remains difficult with a low targeting rate worldwidely. Currently, hyperuricemia classification has not been widely applied to the management of gout owing to insufficient clinical evidences. This study aimed to evaluate the effectiveness of achieving target urate based on hyperuricemia classification in Chinese patients with gout.MethodsIn this prospective study, patients with gout receiving urate lowering therapy with benzbromarone were assigned to two groups, a renal underexcretion and an unclassified type. The primary endpoint was the proportion of patients achieving the serum urate target (<360 μmol/L) during the 12-week study. The frequency of acute gout attacks as well as physical and chemical indicators were secondary endpoints.ResultsTarget serum urate level was achieved in 60.5% of underexcretors compared with 39.0% of patients of the unclassified type at week 12 (P = 0.002). Blood glucose and cholesterol levels were lower in the underexcretor group compared with the unclassified type group at the end of the trial, without significant different frequencies in gout flare during the study. In subgroup analysis, stratified by body mass index and estimated glomerular filtration rate, the proportion of patients with serum urate <360 μmol/L was greater in the underexcretion compared with the unclassified type group.ConclusionsThe increased achievement of target serum urate in the underexcretion group supports the use of a clinical hyperuricemia typing treatment strategy for gout.

【 授权许可】

Unknown   
Copyright © 2022 Xue, Yuan, Han, Li, Merriman, Cui, Liu, Sun, Wang, Yan, He, Ji, Lu and Li.